Avanos Medical, Inc.
AVNS
$13.11
-$0.01-0.08%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.72% | 4.34% | 1.92% | 0.84% | 3.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.72% | 4.34% | 1.92% | 0.84% | 3.64% |
| Cost of Revenue | 16.30% | 18.45% | 8.94% | 8.98% | 4.21% |
| Gross Profit | -12.24% | -7.43% | -3.66% | -5.27% | 3.16% |
| SG&A Expenses | -4.39% | 3.90% | 3.21% | -8.35% | 10.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -166.67% | 483.33% | -85.71% | -900.00% | 110.00% |
| Total Operating Expenses | 4.85% | 11.93% | 4.29% | -2.42% | 8.19% |
| Operating Income | -65.71% | -95.83% | -60.32% | 106.00% | -38.24% |
| Income Before Tax | 100.29% | -112.63% | -1,324.19% | 546.67% | -4,824.72% |
| Income Tax Expenses | 110.64% | -94.44% | -52.63% | 210.00% | -1,019.05% |
| Earnings from Continuing Operations | 99.67% | -123.73% | -1,886.05% | 1,220.00% | -3,709.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 40.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 99.67% | -132.56% | -4,366.67% | 833.33% | -3,883.81% |
| EBIT | -65.71% | -95.83% | -60.32% | 106.00% | -38.24% |
| EBITDA | -37.50% | -58.23% | -28.98% | 21.34% | -24.21% |
| EPS Basic | 99.68% | -132.30% | -4,331.38% | 834.36% | -3,899.82% |
| Normalized Basic EPS | -73.16% | -108.37% | -82.46% | 289.05% | -41.93% |
| EPS Diluted | 99.68% | -135.24% | -4,711.11% | 800.00% | -3,900.70% |
| Normalized Diluted EPS | -73.16% | -108.48% | -82.32% | 286.57% | -41.43% |
| Average Basic Shares Outstanding | 0.87% | 0.87% | 0.87% | -0.22% | -0.43% |
| Average Diluted Shares Outstanding | 0.87% | -0.43% | 0.00% | 0.21% | -1.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |